- Home
- Publications
- Publication Search
- Publication Details
Title
Quo Vadis—Do Immunotherapies Have a Role in Glioblastoma?
Authors
Keywords
Glioblastoma, Tumor microenvironment, Immunotherapy, Checkpoint inhibition, PD-1/PD-L1 pathway, Anti-glioma vaccine, CAR T cells
Journal
Current Treatment Options in Neurology
Volume 20, Issue 5, Pages -
Publisher
Springer Nature
Online
2018-04-18
DOI
10.1007/s11940-018-0499-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- (2017) Michael Weller et al. LANCET ONCOLOGY
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- ATIM-08. IMMUNOMARKERS IN THE DNX-2401 (DELTA-24-RGD) ONCOLYTIC VIRUS PHASE I CLINICAL TRIAL
- (2017) Juan Fueyo et al. NEURO-ONCOLOGY
- Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma
- (2017) Maria-Carmela Speranza et al. NEURO-ONCOLOGY
- CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014
- (2017) Quinn T Ostrom et al. NEURO-ONCOLOGY
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
- (2017) Antonio Omuro et al. NEURO-ONCOLOGY
- OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143
- (2017) D. A. Reardon et al. NEURO-ONCOLOGY
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma
- (2017) Nabil Ahmed et al. JAMA Oncology
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
- (2016) Jennifer E. Kim et al. CLINICAL CANCER RESEARCH
- Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
- (2016) Eric Bouffet et al. JOURNAL OF CLINICAL ONCOLOGY
- A polarizing question: do M1 and M2 microglia exist?
- (2016) Richard M Ransohoff NATURE NEUROSCIENCE
- ATIM-11. PHASE 2 TRIAL OF SL-701, A NOVEL IMMUNOTHERAPY COMPRISED OF SYNTHETIC SHORT PEPTIDES AGAINST GBM TARGETS IL-13Rα2, EphA2, AND SURVIVIN, IN ADULTS WITH SECOND-LINE RECURRENT GBM: INTERIM RESULTS
- (2016) David Reardon et al. NEURO-ONCOLOGY
- Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies
- (2016) Sarah T. Garber et al. NEURO-ONCOLOGY
- A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
- (2016) Alba A. Brandes et al. NEURO-ONCOLOGY
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma
- (2016) ZENGJIN LIU et al. Oncology Letters
- The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy
- (2016) Sung-Min Ahn et al. Oncotarget
- Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment
- (2015) Hinke F. van Thuijl et al. ACTA NEUROPATHOLOGICA
- Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
- (2015) C. E. Brown et al. CLINICAL CANCER RESEARCH
- A Genetically Modified Adenoviral Vector with a Phage Display-Derived Peptide Incorporated into Fiber Fibritin Chimera Prolongs Survival in Experimental Glioma
- (2015) Julius W. Kim et al. HUMAN GENE THERAPY
- The role of STAT3 in tumor-mediated immune suppression
- (2015) Sherise D. Ferguson et al. JOURNAL OF NEURO-ONCOLOGY
- OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy
- (2015) Ichiyo Shibahara et al. Molecular Cancer
- Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
- (2015) Duane A. Mitchell et al. NATURE
- SomaticPOLEmutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis
- (2015) E. Zeynep Erson-Omay et al. NEURO-ONCOLOGY
- A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
- (2015) J. Schuster et al. NEURO-ONCOLOGY
- PD-L1 expression and prognostic impact in glioblastoma
- (2015) Edjah K. Nduom et al. NEURO-ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
- (2015) Laura A. Johnson et al. Science Translational Medicine
- Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
- (2015) D. B. Johnson et al. Cancer Immunology Research
- Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator of Transcription 3 Pathway in Glioblastoma
- (2015) John de Groot et al. Oncotarget
- Autologous T-cell Therapy for Cytomegalovirus as a Consolidative Treatment for Recurrent Glioblastoma
- (2014) A. Schuessler et al. CANCER RESEARCH
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Tim-3 on Peripheral CD4+ and CD8+ T Cells Is Involved in the Development of Glioma
- (2014) Song Han et al. DNA AND CELL BIOLOGY
- RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
- (2014) Yanping Xiao et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A vaccine targeting mutant IDH1 induces antitumour immunity
- (2014) Theresa Schumacher et al. NATURE
- FIRST-IN-HUMAN PHASE I CLINICAL TRIAL OF ONCOLYTIC DELTA-24-RGD (DNX-2401) WITH BIOLOGICAL ENDPOINTS: IMPLICATIONS FOR VIRO- IMMUNOTHERAPY
- (2014) F. F. Lang et al. NEURO-ONCOLOGY
- Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
- (2014) Anna Sophie Berghoff et al. NEURO-ONCOLOGY
- AT-60 * A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 2 TRIAL OF DENDRITIC CELL (DC) VACCINE ICT-107 FOLLOWING STANDARD TREATMENT IN NEWLY DIAGNOSED PATIENTS WITH GBM
- (2014) P. Wen et al. NEURO-ONCOLOGY
- Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients
- (2014) YASUTO AKIYAMA et al. ONCOLOGY REPORTS
- Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model
- (2014) Zineb Belcaid et al. PLoS One
- Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages
- (2013) O. Bloch et al. CLINICAL CANCER RESEARCH
- The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma
- (2013) Qi Yue et al. JOURNAL OF NEURO-ONCOLOGY
- Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial
- (2013) Orin Bloch et al. NEURO-ONCOLOGY
- Expression of Indoleamine 2,3-Dioxygenase and Correlation With Pathological Malignancy in Gliomas
- (2013) Kentaro Mitsuka et al. NEUROSURGERY
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- Genetically Modified T Cells to Target Glioblastoma
- (2013) Simone Krebs et al. Frontiers in Oncology
- Human Leukocyte Antigen-G Is Frequently Expressed in Glioblastoma and May Be Induced in Vitro by Combined 5-Aza-2′-Deoxycytidine and Interferon-γ Treatments
- (2012) Isabela J. Wastowski et al. AMERICAN JOURNAL OF PATHOLOGY
- Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
- (2012) Surasak Phuphanich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor-Modified T Cells
- (2012) S. Kong et al. CLINICAL CANCER RESEARCH
- IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
- (2012) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein
- (2012) C. A. Crane et al. CLINICAL CANCER RESEARCH
- Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma
- (2012) Richard A. Morgan et al. HUMAN GENE THERAPY
- HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells
- (2012) Fabian Wolpert et al. JOURNAL OF NEUROIMMUNOLOGY
- STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression
- (2012) Shinji Kohsaka et al. MOLECULAR CANCER THERAPEUTICS
- Unknown
- (2012) Salvatore Coniglio et al. MOLECULAR MEDICINE
- T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
- (2012) Kevin KH Chow et al. MOLECULAR THERAPY
- Consensus on the role of human cytomegalovirus in glioblastoma
- (2012) K. Dziurzynski et al. NEURO-ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion
- (2011) Kimberly A. Hofmeyer et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
- (2011) P. Hemon et al. JOURNAL OF IMMUNOLOGY
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
- (2011) B. Raychaudhuri et al. NEURO-ONCOLOGY
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oleanolic acid inhibits macrophage differentiation into the M2 phenotype and glioblastoma cell proliferation by suppressing the activation of STAT3
- (2011) Yoshihiro Komohara ONCOLOGY REPORTS
- HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors
- (2010) N. Ahmed et al. CLINICAL CANCER RESEARCH
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
- (2010) John H. Sampson et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tolerogenic Dendritic Cells Generated with Different Immunosuppressive Cytokines Induce Antigen-Specific Anergy and Regulatory Properties in Memory CD4 + T Cells
- (2010) Honorio Torres-Aguilar et al. JOURNAL OF IMMUNOLOGY
- The detection of CMV pp65 and IE1 in glioblastoma multiforme
- (2010) Kenneth G. Lucas et al. JOURNAL OF NEURO-ONCOLOGY
- Prognostic significance and mechanism of Treg infiltration in human brain tumors
- (2010) Joannes F.M. Jacobs et al. JOURNAL OF NEUROIMMUNOLOGY
- Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway
- (2010) J. Wei et al. MOLECULAR CANCER THERAPEUTICS
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
- (2010) J. H. Sampson et al. NEURO-ONCOLOGY
- Glioma cancer stem cells induce immunosuppressive macrophages/microglia
- (2010) Adam Wu et al. NEURO-ONCOLOGY
- Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors
- (2009) Rebecca Liu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Systemic Inhibition of Transforming Growth Factor- in Glioma-Bearing Mice Improves the Therapeutic Efficacy of Glioma-Associated Antigen Peptide Vaccines
- (2009) R. Ueda et al. CLINICAL CANCER RESEARCH
- MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance
- (2009) S. Yip et al. CLINICAL CANCER RESEARCH
- Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice
- (2009) Leying Zhang et al. GLIA
- IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
- (2009) Lin Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
- (2009) J. H. Sampson et al. MOLECULAR CANCER THERAPEUTICS
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion
- (2008) Rose Du et al. CANCER CELL
- Low-Dose Radiation Enhances Survivin-Mediated Virotherapy against Malignant Glioma Stem Cells
- (2008) S. Nandi et al. CANCER RESEARCH
- Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas
- (2008) A. B. Heimberger et al. CLINICAL CANCER RESEARCH
- Neural stem/progenitor cells modulate immune responses by suppressing T lymphocytes with nitric oxide and prostaglandin E2
- (2008) Lei Wang et al. EXPERIMENTAL NEUROLOGY
- A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy
- (2008) Toshihiko Wakabayashi et al. JOURNAL OF GENE MEDICINE
- Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas
- (2008) Y Komohara et al. JOURNAL OF PATHOLOGY
- A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma
- (2008) E Antonio Chiocca et al. MOLECULAR THERAPY
- A Phase I Trial of Intratumoral Administration of Reovirus in Patients With Histologically Confirmed Recurrent Malignant Gliomas
- (2008) Peter Forsyth et al. MOLECULAR THERAPY
- Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors
- (2008) Joannes F.M. Jacobs et al. NEURO-ONCOLOGY
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
- Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study
- (2007) Amy B. Heimberger et al. NEURO-ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started